iBio In Collaboration With AstralBio, Announced The Development Of An Antibody That Inhibits The Function Of Activin E, Therapeutic Target For Cardiometabolic Disorders And Obesity Using iBio's Machine-learning Antibody Engine

Benzinga · 01/07 12:24

iBio plans to rapidly advance testing of this molecule and additional candidates in more complex and disease relevant models.